Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
Plos One
|
April 18, 2019
Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system
Jang Ho Cho, Ju-Sun Kim, Seung Tae Kim, et al.
Clinical Lung Cancer
|
August 24, 2022
A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11)
Kyung Hwan Kim, Shinkyo Yoon, Hee Kyung Ahn, et al.
The Korean Journal of Internal Medicine
|
August 15, 2020
Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia
Jang Ho Cho, Joon-Ho Shim, Sang Eun Yoon, et al.
Cancer Research and Treatment
|
July 28, 2018
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon, Youjin Kim, Sung Won Lim, et al.
Head & Neck
|
May 21, 2026
Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study
Sang Hoon Chun, Seyoung Seo, Jang Ho Cho, et al.
Cancer
|
October 27, 2021
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)
Hongsik Kim, Dong-Wan Kim, Miso Kim, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 1, 2018
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
Sung Won Lim, Sehhoon Park, Youjin Kim, et al.
BMC Cancer
|
January 19, 2019
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea
Hee Kyung Kim, Soo-Hyeon Lee, Yu Jin Kim, et al.
Cancer Research and Treatment
|
September 8, 2018
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
Hee Kyung Kim, Kyung Hee Park, Youjin Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2019
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
Jang Ho Cho, Sung Hee Lim, Ho Jung An, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
Plos One
|
April 18, 2019
Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system
Jang Ho Cho, Ju-Sun Kim, Seung Tae Kim, et al.
Clinical Lung Cancer
|
August 24, 2022
A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11)
Kyung Hwan Kim, Shinkyo Yoon, Hee Kyung Ahn, et al.
The Korean Journal of Internal Medicine
|
August 15, 2020
Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia
Jang Ho Cho, Joon-Ho Shim, Sang Eun Yoon, et al.
Cancer Research and Treatment
|
July 28, 2018
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon, Youjin Kim, Sung Won Lim, et al.
Head & Neck
|
May 21, 2026
Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study
Sang Hoon Chun, Seyoung Seo, Jang Ho Cho, et al.
Cancer
|
October 27, 2021
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)
Hongsik Kim, Dong-Wan Kim, Miso Kim, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 1, 2018
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
Sung Won Lim, Sehhoon Park, Youjin Kim, et al.
BMC Cancer
|
January 19, 2019
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea
Hee Kyung Kim, Soo-Hyeon Lee, Yu Jin Kim, et al.
Cancer Research and Treatment
|
September 8, 2018
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
Hee Kyung Kim, Kyung Hee Park, Youjin Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2019
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
Jang Ho Cho, Sung Hee Lim, Ho Jung An, et al.
Page
of 4